Followers | 230 |
Posts | 15196 |
Boards Moderated | 0 |
Alias Born | 03/30/2005 |
Wednesday, September 23, 2020 10:57:50 AM
initially i was hoping with no official announcement that the RBL was done in August, maybe IPIX was working behind the scenes to hit investors with a big update. I was wrong since 1 month later IPIX issued the same language of 'rbl nearing completion'
i admire those who feel the company is doing things behind the scenes, however they are setting the bar very high. There are rumors floating around via pm which i hope are true, but if IPIX pushes back the timeline or says they have yet to meet with CTAP/FDA, it won't be good imho
Each time IPIX hired a CDMO in the past, they PR'd it (because it is a material event). No CDMO = no timeframe for Brilacidin IV for Covid = IND delays. There has been vague language as to the preparation for manufacturing B and even a hint at potential excess B based on trial projections, but i don't see how this is possible without a cdmo
I hope the others are right and I am wrong. i appreciate those on twitter trying to spread the word. this far in the game, it looks as if ipix is just leaning on the RBL and possible peer review article. Maybe this is my last minute jitters but we are approaching October at warp speed and there has been no clear path laid out to get into human trial this year other than to say we'll brilacidin will be in human trial later this year.
the above is all IMHO (consider this my safe harbor statement)
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM